1 / 53

[trainer] [email/contact details]

A 2 day workshop [month] [ day 1 ],[day2] [location] Developed by Neil Hunt and Andrew Preston Run by:. assessing drug transitions & developing interventions to promote safer drug use. [trainer] [email/contact details]. [trainer] [email/contact details]. Ethos.

meagan
Download Presentation

[trainer] [email/contact details]

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. A 2 day workshop[month] [day 1],[day2][location]Developed by Neil Hunt and Andrew PrestonRun by: assessing drug transitions & developing interventionsto promote safer drug use [trainer] [email/contact details] [trainer] [email/contact details]

  2. Ethos • Acknowledge what we don’t know • Ask when we don’t understand (there’s no such thing as a silly question!) • Be generous and confident with our ideas and views and those of others • Be open to the literature and evidence…but questioning • Think creatively

  3. Programme structure • Day 1 • Introductions – ourselves & our services • Different drugs and routes of administration • The first hit • Day 2 • Transition theory and interventions • Adapting and using the data collection tool to inform interventions • Evaluation and close

  4. Definitions • Route transitions • A temporary or permanent transition in the way that a drug is administered • Route transition interventions • An intervention that either: a) attempts to prevent the transition to a more harmful route of drug administration such as injecting; or b) promotes the use of a safer route of drug administration

  5. Learning objectives • Discuss the literature on drug transitions relating to heroin use and injecting • Understand route transitions interventions that have been used elsewhere and the evidence of their effectiveness • Provisionally evaluate which (if any) interventions may be most applicable for participants • Appraise and revise a transitions data collection instrument to assess local needs • Assess how best to use the instrument to inform the development of your own services

  6. Health needs and priorities • What are the health priorities for injecting drug users in your area? [needs] • what services to do you have and what are your priorities? [responses] • needle exchange (centre based and/or outreach) • methadone prescribing (is it low threshold, high dose?) • residential rehabilitation • overdose prevention information • community detoxification programmes • prevention of transition to injecting interventions • basic healthcare, housing, human rights, other…

  7. Heroin use, injecting and the ‘first hit’ • Limitations to the evidence-base • Factors associated with using heroin/injecting • Reasons people use or avoid heroin/injecting • Issues associated with the first hit

  8. Limitations to the evidence base • The evidence is largely derived from treatmentpopulations • Learning from the literature cannot be assumed to be entirely transferable to the regions that concern us • Heroin use/injecting can be subject to rapid epidemiological change

  9. Factors associated with using heroin/injecting • Age – a youth phenomenon • Albania, Bosnia and Herzegovina, Croatia, the Federal Republic of Yugoslavia and the Former Yugoslav Republic of Macedonia - Mean age of first injection 17.3 – 19.1yrs (Wong 2002) • Serbia/Montenegro - Mean age of first injection is 18.2yrs  (Cucic 2002) • Gender – predominantly male • Tends to be between 3:1 and 4:1 • Socio-economic status • strongly associated with poverty and urbanisation • Ethnicity • associations with membership of a minority population e.g. Russians in Estonia, Roma.

  10. Key issues associated with the ‘first hit’ • Modelling/social exposure • Peer influence and the desire to try ‘just once’ • The role of alcohol and other drugs on risk taking • Type of drug • Drug buying arrangements • Risk management • Blood borne infections • Bacterial infection • Overdose • Dependence

  11. Reasons people use or avoid heroin/injecting • Fear of addiction • Fear of HIV/AIDS • Lack of knowledge/technical proficiency • Fear of needles • Stigma of heroin use/injecting • But….no evidence that increased availability of needles and syringes increases prevalence of injecting • Curiosity • The ‘rush’ • Economics • Peer/partner influence • Anomie/self medication • Cultural norms • Availability • Diffusion of innovation • Managing post-stimulant ‘come down’ • Associations of injecting with modernity/potency • Glamour and heroin ‘chic’

  12. A 2 day workshop[month] [day 1],[day2][location]Developed by Neil Hunt and Andrew PrestonRun by: assessing drug transitions & developing interventionsto promote safer drug use [trainer] [email/contact details] [trainer] [email/contact details]

  13. Route transitions theory, history and evidence • Early 1990s – developments in the systematic study of transitions • Griffiths et al 1994 • Darke et al 1994

  14. Griffiths et al. 1994 • 408 heroin users (community sample) • 54% preferred injecting • 44% preferred chasing • More than a third had changed their preferred route (transition) “a change in the exclusive or predominant route of administration lasting one month or more” • Transitions were • Usually chasing to injecting • Multiple transitions uncommon • But…16% of chasers had previously been regular injectors • And…many chasers had not adopted injecting despite using at high doses for many years

  15. Darke et al. 1994 • 301 regular amphetamine users (community sample) • Transition defined as “a change in the usual route of administration lasting four or more occasions of amphetamine use” • First route of use: • Inject 23% • Snort 58% • Swallow 19% • Smoke 1% • 40% had made a transition to injecting from another route of use because of a) the rush b) more economical c) cleaner • 9% had made a transition from injecting • Main reason was concern about vascular damage

  16. The road to interventions • Need to • “take account of current administration and the potential for future transitions” (Griffiths et al. 1994) • “Address the misconceptions that injecting is more economical and more healthy, and to emphasise the vascular problems associated with injecting” (Darke et al. 1994) • Renewed interest in circumstances surrounding initiation into injecting – ‘the first hit’ (Crofts et al, 1996) • In the context of epidemic hepatitis C in the contact Alex Wodak suggested that harm reductionists should promote Non-Injecting Routes of Administration – NIROA (1997)

  17. Subsequent initiation and transitions studies • Australia (John Howard) • Canada (Elise Roy) • Ukraine – work in progress (Olga Balakireva, Cas Berendregt, Jean Paul Grund et al) • Young and occasional injectors -UNICEF/CEEHRN meeting (Howard, Hunt and Arcuri 2003) • PSI 2004!

  18. Motivation and change Pre contemplation > contemplation > action > maintenance > relapse

  19. ‘Route transitions interventions’Hunt et al. 1999 • Two main targets for intervention • Prevent people from beginning to inject drugs they are using • Encourage people to switch from injecting to a safer route

  20. Preventing commencement 1 • Working with ‘at risk’ users (Casriel et al. 1990, Des Jarlais et al 1992) • Targeted heroin sniffers • Four part ‘psycho-educational programme’ • Intervention group less significantly less likely to transition • Transitions 14/43 controls 6/40 experimental group • But…hard to contact and recruit

  21. Preventing commencement 2 • Working with current injectors ‘Break the cycle’ (Hunt et al. 1998) • Three month follow up study (73/86 recontacted) • One-to-one structured intervention to discourage practises among current IDUs that increase risk of transition of others • Uncontrolled trial • Significant reductions in ‘modelling’ injecting, willingness to initiate others, initiation requests and initiations (before and after intervention)

  22. Preventing commencement 3 • Methadone treatment for non-injecting heroin users (Southwell et al. 1997)

  23. Switching (prescribing) Oral maintenance • Methadone (Strang et al. 1997) • Buprenorphine (increasingly and especially people on lower doses of heroin) • Dexamphetamine (largely pilot work) Smokeable maintenance • Heroin reefers (Marks and Palombella 1991) • Heroin inhalation (van den Brink et al 2002)

  24. Social marketing approaches • Promoting heroin smoking • The chasing campaign (Healthy Options Team) • How to chase (Lifeline) • Promoting rectal administration • Up Your Bum (Southwell/HIT) • Promoting sniffing? • Broad-based, population-wide campaigns that focus on injecting rather than drug use • But….no evaluations to date

  25. Intervening in drug markets? • Certain formulations of drugs have greater ‘injectability’ than others…compare brown and white heroin • Historically, the impact of drug interdiction efforts has been questionable but…might it be possible to intervene in a way that favours less readily injected drugs (where applicable)? (Strang and King 1997)

  26. Route Transition Interventions overview • Preventing transition • Group-based • Break the cycle • Switching • Methadone and other substitutes • Heroin reefers/prescribing • Social marketing – How to chase/Up your bum • Over-arching • Broad based social marketing re: injecting • Intervening in drug markets

  27. Three Key Points • The intervention is simply a structured conversation about initiation • It should never be used coercively • Work to prevent initiation of others is secondary to that concerning the immediate health and well-being of the injector

  28. Injecting As An Especially Risk-laden Form Of Drug Use • Blood-borne viruses and other infections • Overdose • Increased dependence

  29. The Initiation Process 1 • People don’t generally plan to start injecting when they start using drugs • They usually learn about injecting by watching injectors and talking about it

  30. The Initiation Process 2 • They often ask existing injectors to give them their first hit • Injectors are often reluctant to do this but may have difficulty in dealing with such requests

  31. The Intervention Aims • Enable people to think about their attitude to initiating others • Develop resistance to initiating others • Increase awareness of actions that make it more likely that others will start • Enhance ability to manage initiation requests

  32. The Intervention • Introducing the conversation • Assessment • Their initiation history • Experience of initiating others • Initiation risks • To them • To the new injector • Social learning • Discuss difficult situations

  33. Research results • Only 7% felt pressure to inject had been important for them • 61% felt talking about injecting had influenced their initiation • 67% felt seeing others had been important in their initiation • 84% had injected in front of a non-injector (59% in the past 3 months) • Less than 25% had discussed initiation with a treatment worker

  34. Evaluation Results • Injecting in front of non-injectors was halved (97 to 49) • Disapproval of initiating others was increased (12 item attitude scale) • Participants received fewer than half as many requests to initiate someone (36 to 15) • The number of people initiated by participants fell (6 to 2)

  35. The ‘Break The Cycle’ Campaign • The intervention briefing • An intervention pad – 30 tear off cards • A leaflet • A poster

  36. Three Key Points • The intervention is simply a structured conversation about initiation • It should never be used coercively • Work to prevent initiation of others is secondary to that concerning the immediate health and well-being of the injector

  37. Can BTC be delivered as a using a higher coverage, peer-delivered model?

  38. Aims • To test the feasibility of implementing a peer-delivered intervention to reduce initiation into injecting - the ‘Break the cycle campaign’ • Can it be done? • Process evaluation • What happens when you try to do this • How might it be done better? • Intermediate outcome data • What impact, if any, does it have on drug users?

  39. The main messages You inject but that doesn’t always mean that you encourage others to do the same. But - without meaning to that’s exactly what you could be doing by: • Talking about injecting to non-injectors • Injecting in front of non-injectors So - giving people their first hit. Consider whether this is something you are always ok about doing?

  40. Design 1 • All NSP users were seen as potential ‘disseminators’ of the Break the Cycle (BTC) message • Those who consented were given • an explanation of the aims • a pack of BTC materials • For each ‘recipient’ in their social network who later presented back to the service and could successfully repeat the main campaign messages they were paid £5 (up to a maximum of 5 people - £25) • When collecting their payment disseminators were asked to complete a questionnaire

  41. Design 2 • All recipients who could recite the main messages of the campaign to a member of the needle exchange staff were paid £5 • They also completed a research questionnaire • People who had not used the NSP before also completed a risk behaviour audit • Anonymity was maintained throughout by the use of credit card system that enabled disseminators and recipients to be linked

  42. Results - process • Duration – Bolton (10 weeks) • 18 disseminators recruited • 73 recipients attended service • Leigh (4 weeks) • 31 disseminators recruited • 108 recipients attended service

  43. Disseminators • Data available for 37/49 • 30 male (81%) • Mean age 30 (19-43) • Injecting an average of 8 years (but 2 people less than one year)

  44. Disseminators • Number of injectors known locally (median 30, range 8-300) • Number known well enough to discuss BTC with? (median 10, range 2-80) • Number you spoke to about the BTC campaign? (median 10, range 3-70) • Number you gave the BTC leaflet? (median 9.5, range 0-70) • Ever asked to give someone first hit (86%) • Even given someone first hit (43%)

  45. Recipients • Data available for 177/181 • 130 male (75%) slightly fewer than disseminators • Age mean 28, median 28, range 18-45 • Injecting an average of 8 years (but 14 people for one year or less) • 18 people who were new to the NSP

  46. Experience of initiation • Ever been asked for first hit? 49% • Ever given first hit? 22% • Ever talked with drug user about giving someone first hit? 62% • Ever talked with drug worker about giving someone first hit? 27%

  47. Risk behaviour audit (%) (new NSP users)

  48. Learning points • To do this absorbed lots of energy and effort • It is feasible • Non-staff costs were about £2000 • The anonymised linking system for payments worked • It got 18 new people through the NSP door (added value beyond the primary study aim) • It was crucial to manage demand properly. The service was swamped at times! • We should have stipulated that recipients cannot return sooner than 24 hours after the disseminator is recruited

  49. Residual questions and issues • Data validity? • Effectiveness/cost effectiveness? • Ethics of paying people to receive health messages?

More Related